Welcome to our dedicated page for Blueprint Medicines SEC filings (Ticker: BPMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Blueprint Medicines Corp. filings document the company’s biopharmaceutical issuer history, common stock registration, governance votes and corporate-status reporting. Recent Form 8-K disclosures include annual meeting matters such as director elections and advisory executive compensation votes, while Form 15 records the termination of registration or suspension of Exchange Act reporting duties for the company’s common stock.
The filing record also reflects capital-structure disclosure, stockholder voting procedures, registered-security information and material-event reporting associated with Blueprint Medicines’ public-company obligations.
Blueprint Medicines Corp. (NASDAQ: BPMC) filed Amendment No. 1 to its Schedule 14D-9, updating shareholders on Sanofi’s $129.00-per-share cash tender offer plus a non-transferable contingent value right (CVR) worth up to an additional $6.00 per share. The amendment provides supplemental disclosure on (i) financial advisor valuation work and (ii) regulatory and legal developments.
Financial advisor analyses. Centerview’s discounted cash-flow (DCF) generated an implied equity value range of $115.80-$148.50 per share, while Jefferies’ DCF showed $112.50-$143.65. Both were benchmarked against the implied consideration of approximately $131.00 (cash + CVR midpoint). Centerview’s precedent-premium study implied $136.80-$187.50 per share. Historical trading over the prior 52 weeks ranged $79.22-$120.50; 21 sell-side price targets ranged $83-$167 (median $130).
Regulatory clearances achieved. The U.S. HSR waiting period expired on 9 July 2025, satisfying a key closing condition. Clearance milestones were also reached in Austria (8 July 2025), Germany (30 June 2025) and Italy (25 June 2025, Golden Power exemption). These approvals materially reduce antitrust risk for the transaction.
Legal proceedings. Two shareholder suits (Williams and Phillips) filed in New York allege the Schedule 14D-9 is materially incomplete; 12 additional demand letters request further disclosure. The company denies wrongdoing but voluntarily provided the new disclosures to mitigate delay or expense.
Bottom line. The amendment does not change economic terms, but confirms multiple regulatory approvals and reveals valuation ranges that largely bracket the $131 offer, supporting fairness. Litigation represents a manageable but ongoing risk.
Blueprint Medicines Corporation (BPMC) director Jeffrey W. Albers received a significant equity grant on June 18, 2025. The transaction involved 3,902 restricted stock units (RSUs) awarded at a price of $128.12 per share.
Key details of the RSU grant:
- Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents one share of common stock
- Following the transaction, Albers directly owns 150,532 shares
This Form 4 filing, signed by attorney-in-fact Melissa Masse on June 23, 2025, reflects standard director compensation practices and demonstrates continued alignment between board members and shareholder interests through equity-based compensation.
Blueprint Medicines Corp (BPMC) Director Mark Alan Goldberg received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, valued at $128.12 per share. Following this transaction, Goldberg directly owns 22,156 shares of common stock.
Key details of the RSU grant:
- Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents the right to receive one share of common stock
- Total value of granted RSUs: approximately $500,000
This Form 4 filing, executed by attorney-in-fact Melissa Masse on June 23, 2025, represents standard equity compensation for a board member, aligning director interests with shareholders through stock ownership.